Top Markets
Coin of the day
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
株式のランク #14772
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
株価
$16.85
最終同期: 2023-07-07
時価総額
$393.50M
変化(1日)
0.00%
変化(1年)
0.00%
CH
取引 VectivBio Holding AG (VECT)

カテゴリー

VectivBio Holding AG(VECT)の配当利回りの履歴
VectivBio Holding AG(銘柄コード: VECT)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
VectivBio Holding AG(VECT)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)